Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114308 · ClinicalTrials.gov registry record · Phase 3
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT01114308: Completed Phase 3 study, sponsored by Titan Pharmaceuticals.
NCT01114308 is a Phase 3 study that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 287 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114308, a Phase 3 study, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphine in the treatment of patients with opioid dependence.
Interventions
- DRUG Buprenorphine
- DRUG Probuphine (buprenorphine implant)
- DRUG placebo implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT01114308 record still lists
NCT01114308 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT01114308 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01114308 about?
NCT01114308 is a clinical study titled "A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction". Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphi...
What is the current status of trial NCT01114308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2010-04. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01114308?
The interventions under investigation include: Buprenorphine (DRUG), Probuphine (buprenorphine implant) (DRUG), placebo implant (DRUG).
Who is sponsoring clinical trial NCT01114308?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01114308's enrollment target sits among peer trials
287 1182nd of 2000 higher than 819 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia